JP2004517894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517894A5 JP2004517894A5 JP2002557938A JP2002557938A JP2004517894A5 JP 2004517894 A5 JP2004517894 A5 JP 2004517894A5 JP 2002557938 A JP2002557938 A JP 2002557938A JP 2002557938 A JP2002557938 A JP 2002557938A JP 2004517894 A5 JP2004517894 A5 JP 2004517894A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- amine
- methyl
- ring
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000001931 aliphatic group Chemical group 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- -1 alkoxyalkylamino Chemical group 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108090000461 Aurora Kinase A Proteins 0.000 description 2
- 102100032311 Aurora kinase A Human genes 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- MEVHTHLQPUQANE-UHFFFAOYSA-N aziridine-2,3-dione Chemical compound O=C1NC1=O MEVHTHLQPUQANE-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CXLPODKWPHSQEB-UHFFFAOYSA-N 2-(dimethylamino)-n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)CN(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 CXLPODKWPHSQEB-UHFFFAOYSA-N 0.000 description 1
- OKUQCAXYWXFGPK-UHFFFAOYSA-N 2-[(3,5-dimethoxyphenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(CSC=2N=C(C=C(NC=3NN=C(C)C=3)N=2)N2CCOCC2)=C1 OKUQCAXYWXFGPK-UHFFFAOYSA-N 0.000 description 1
- XRAFMWYIOALWSA-UHFFFAOYSA-N 2-[(3,5-dimethoxyphenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-pyrrolidin-3-ylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(CSC=2N=C(C=C(NC=3NN=C(C)C=3)N=2)C2CNCC2)=C1 XRAFMWYIOALWSA-UHFFFAOYSA-N 0.000 description 1
- MPSNETNZTLYXIK-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 MPSNETNZTLYXIK-UHFFFAOYSA-N 0.000 description 1
- LUJIOOSJBZJHHK-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-n-(2-methoxyethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(SCC=2C=C(Cl)C=CC=2)=NC(NCCOC)=CC=1NC1=CC(C)=NN1 LUJIOOSJBZJHHK-UHFFFAOYSA-N 0.000 description 1
- VWRGZMRMYRYZGQ-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 VWRGZMRMYRYZGQ-UHFFFAOYSA-N 0.000 description 1
- MSENMMQDNAUODA-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-piperidin-1-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCCCC2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 MSENMMQDNAUODA-UHFFFAOYSA-N 0.000 description 1
- JUPXIGULOXFQHK-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylsulfanyl]-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CSC1=NC(NC=2NN=C(C)C=2)=CC(N2CCN(C)CC2)=N1 JUPXIGULOXFQHK-UHFFFAOYSA-N 0.000 description 1
- WOGTVCHVDBTSJN-UHFFFAOYSA-N 2-benzylsulfanyl-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(SCC=2C=CC=CC=2)=N1 WOGTVCHVDBTSJN-UHFFFAOYSA-N 0.000 description 1
- RHCLBIQUEJRCEF-UHFFFAOYSA-N 2-benzylsulfanyl-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=CC=CC=2)=N1 RHCLBIQUEJRCEF-UHFFFAOYSA-N 0.000 description 1
- FYAPZIAUATWNOR-UHFFFAOYSA-N 3-methyl-n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]butanamide Chemical compound C1=CC(NC(=O)CC(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 FYAPZIAUATWNOR-UHFFFAOYSA-N 0.000 description 1
- GOYHGLIVSBBDEG-UHFFFAOYSA-N 6-(2,6-dimethylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C(=CC=CC=2C)C)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 GOYHGLIVSBBDEG-UHFFFAOYSA-N 0.000 description 1
- AIRMEXFVLJJUJE-UHFFFAOYSA-N 6-(2-methylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C(=CC=CC=2)C)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 AIRMEXFVLJJUJE-UHFFFAOYSA-N 0.000 description 1
- QOEQKXHMJLFYIS-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SCC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=N1 QOEQKXHMJLFYIS-UHFFFAOYSA-N 0.000 description 1
- GYWKNWNEMVPCPW-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-methylsulfanylpyrimidin-4-amine Chemical compound C=1C(N2CCN(C)CC2)=NC(SC)=NC=1NC1=CC(C)=NN1 GYWKNWNEMVPCPW-UHFFFAOYSA-N 0.000 description 1
- HYUQZXHOCHTJGO-UHFFFAOYSA-N 6-n-(2-methoxyethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidine-4,6-diamine Chemical compound N=1C(SCC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=NC(NCCOC)=CC=1NC=1C=C(C)NN=1 HYUQZXHOCHTJGO-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FJIJAWAHGQDWTR-UHFFFAOYSA-N methyl 4-[4-(methoxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylbenzoate Chemical compound N=1C(SC=2C=CC(=CC=2)C(=O)OC)=NC(COC)=CC=1NC1=CC(C)=NN1 FJIJAWAHGQDWTR-UHFFFAOYSA-N 0.000 description 1
- UVFVPEIUGCVFRV-UHFFFAOYSA-N methyl 6-[(5-methyl-1h-pyrazol-3-yl)amino]-2-[4-(propanoylamino)phenyl]sulfanylpyrimidine-4-carboxylate Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C(=O)OC)=N1 UVFVPEIUGCVFRV-UHFFFAOYSA-N 0.000 description 1
- OWLHUABMKOEDDP-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound C1CC1C1=NNC(NC=2N=C(SC=3C=C4C=CC=CC4=CC=3)N=CC=2)=C1 OWLHUABMKOEDDP-UHFFFAOYSA-N 0.000 description 1
- HLZNMLOULICIDU-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-5,6-dimethyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound CC=1C(C)=NC(SC=2C=C3C=CC=CC3=CC=2)=NC=1NC(NN=1)=CC=1C1CC1 HLZNMLOULICIDU-UHFFFAOYSA-N 0.000 description 1
- QDLGURJHMBLUKW-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-5-methyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound CC1=CN=C(SC=2C=C3C=CC=CC3=CC=2)N=C1NC(NN=1)=CC=1C1CC1 QDLGURJHMBLUKW-UHFFFAOYSA-N 0.000 description 1
- BFCHWQNHLLJQKU-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C=2)C2CC2)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 BFCHWQNHLLJQKU-UHFFFAOYSA-N 0.000 description 1
- ZKSNPIJCWJYQSS-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-methyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N=1C(SC=2C=C3C=CC=CC3=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1CC1 ZKSNPIJCWJYQSS-UHFFFAOYSA-N 0.000 description 1
- MEQZKLFEMYIESN-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound C1CC1C1=NNC(NC=2N=C(SC=3C=C4C=CC=CC4=CC=3)N=C(C=2)N2CCOCC2)=C1 MEQZKLFEMYIESN-UHFFFAOYSA-N 0.000 description 1
- KXOKAYKGTCLIPO-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanyl-6-phenylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C=CC=CC=2)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 KXOKAYKGTCLIPO-UHFFFAOYSA-N 0.000 description 1
- CEZGBQYQEGPQHG-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-(naphthalen-2-ylmethylsulfanyl)pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=C3C=CC=CC3=CC=2)=N1 CEZGBQYQEGPQHG-UHFFFAOYSA-N 0.000 description 1
- DYWSMDXSVIMMHS-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(SCC=3C=CC(=CC=3)S(=O)(=O)N3CCOCC3)N=C(C=2)N2CCOCC2)=N1 DYWSMDXSVIMMHS-UHFFFAOYSA-N 0.000 description 1
- CWGCAXSXZAOMRF-UHFFFAOYSA-N n-[4-[4-(2-methylphenyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C(=CC=CC=2)C)=N1 CWGCAXSXZAOMRF-UHFFFAOYSA-N 0.000 description 1
- RWEUEIUREFILDS-UHFFFAOYSA-N n-[4-[4-(4-methoxyphenyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(OC)=CC=C1C1=CC(NC=2NN=C(C)C=2)=NC(SC=2C=CC(NC(C)=O)=CC=2)=N1 RWEUEIUREFILDS-UHFFFAOYSA-N 0.000 description 1
- WYIQXFOSEMJMAS-UHFFFAOYSA-N n-[4-[4-(hydroxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(CO)=CC(NC=2NN=C(C)C=2)=N1 WYIQXFOSEMJMAS-UHFFFAOYSA-N 0.000 description 1
- CJITVBOBWKKPLW-UHFFFAOYSA-N n-[4-[4-(methoxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(COC)=CC(NC=2NN=C(C)C=2)=N1 CJITVBOBWKKPLW-UHFFFAOYSA-N 0.000 description 1
- NSJLOJLNMHXHFG-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-morpholin-4-ylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(N2CCOCC2)=N1 NSJLOJLNMHXHFG-UHFFFAOYSA-N 0.000 description 1
- ZUOHNZIRNKHHJE-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 ZUOHNZIRNKHHJE-UHFFFAOYSA-N 0.000 description 1
- GLXTXPWWOYBBCI-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1N=C(C)C=C1NC1=CC(C=2C=CC=CC=2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GLXTXPWWOYBBCI-UHFFFAOYSA-N 0.000 description 1
- NJPTZQZPKSHKNR-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 NJPTZQZPKSHKNR-UHFFFAOYSA-N 0.000 description 1
- FNBGPMNXEGPANM-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 FNBGPMNXEGPANM-UHFFFAOYSA-N 0.000 description 1
- PUUPUZQGYNCCED-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propane-1-sulfonamide Chemical compound C1=CC(NS(=O)(=O)CCC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 PUUPUZQGYNCCED-UHFFFAOYSA-N 0.000 description 1
- MNDVGQRXFSJZGA-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propane-2-sulfonamide Chemical compound C1=CC(NS(=O)(=O)C(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 MNDVGQRXFSJZGA-UHFFFAOYSA-N 0.000 description 1
- BGNRYQCGVJJPRI-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC=CC(NC=2NN=C(C)C=2)=N1 BGNRYQCGVJJPRI-UHFFFAOYSA-N 0.000 description 1
- XGWCSXUNRMZLPZ-UHFFFAOYSA-N n-[4-[4-tert-butyl-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C(C)(C)C)=N1 XGWCSXUNRMZLPZ-UHFFFAOYSA-N 0.000 description 1
- YKDOQPKOCDSGNK-UHFFFAOYSA-N n-[4-[5-methyl-4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=C(C)C(C=2C=CC=CC=2)=N1 YKDOQPKOCDSGNK-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25788700P | 2000-12-21 | 2000-12-21 | |
| US28694901P | 2001-04-27 | 2001-04-27 | |
| PCT/US2001/049401 WO2002057259A2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004366925A Division JP2005097322A (ja) | 2000-12-21 | 2004-12-17 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517894A JP2004517894A (ja) | 2004-06-17 |
| JP2004517894A5 true JP2004517894A5 (enExample) | 2008-03-27 |
| JP4210520B2 JP4210520B2 (ja) | 2009-01-21 |
Family
ID=26946273
Family Applications (19)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565976A Pending JP2004518743A (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002557938A Expired - Fee Related JP4210520B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002559413A Expired - Fee Related JP4160392B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002563142A Expired - Fee Related JP4160395B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002551561A Expired - Fee Related JP4160389B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002567928A Expired - Fee Related JP4234435B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002559414A Pending JP2004517927A (ja) | 2000-12-21 | 2001-12-20 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002551562A Pending JP2004516292A (ja) | 2000-12-21 | 2001-12-20 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2004366925A Withdrawn JP2005097322A (ja) | 2000-12-21 | 2004-12-17 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008095581A Withdrawn JP2008189682A (ja) | 2000-12-21 | 2008-04-01 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008095584A Withdrawn JP2008260767A (ja) | 2000-12-21 | 2008-04-01 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008097620A Pending JP2008222719A (ja) | 2000-12-21 | 2008-04-03 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008098506A Pending JP2008189687A (ja) | 2000-12-21 | 2008-04-04 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121723A Pending JP2008201808A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121727A Pending JP2008247921A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121724A Pending JP2008247920A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2009101481A Expired - Fee Related JP5249842B2 (ja) | 2000-12-21 | 2009-04-17 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2009212566A Withdrawn JP2009286805A (ja) | 2000-12-21 | 2009-09-14 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2013150948A Pending JP2013213068A (ja) | 2000-12-21 | 2013-07-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565976A Pending JP2004518743A (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
Family Applications After (17)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559413A Expired - Fee Related JP4160392B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002563142A Expired - Fee Related JP4160395B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002551561A Expired - Fee Related JP4160389B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002567928A Expired - Fee Related JP4234435B2 (ja) | 2000-12-21 | 2001-12-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002559414A Pending JP2004517927A (ja) | 2000-12-21 | 2001-12-20 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2002551562A Pending JP2004516292A (ja) | 2000-12-21 | 2001-12-20 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2004366925A Withdrawn JP2005097322A (ja) | 2000-12-21 | 2004-12-17 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008095581A Withdrawn JP2008189682A (ja) | 2000-12-21 | 2008-04-01 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008095584A Withdrawn JP2008260767A (ja) | 2000-12-21 | 2008-04-01 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008097620A Pending JP2008222719A (ja) | 2000-12-21 | 2008-04-03 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008098506A Pending JP2008189687A (ja) | 2000-12-21 | 2008-04-04 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121723A Pending JP2008201808A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121727A Pending JP2008247921A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2008121724A Pending JP2008247920A (ja) | 2000-12-21 | 2008-05-07 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2009101481A Expired - Fee Related JP5249842B2 (ja) | 2000-12-21 | 2009-04-17 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2009212566A Withdrawn JP2009286805A (ja) | 2000-12-21 | 2009-09-14 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2013150948A Pending JP2013213068A (ja) | 2000-12-21 | 2013-07-19 | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (16) | US7625913B2 (enExample) |
| EP (10) | EP1345926B1 (enExample) |
| JP (19) | JP2004518743A (enExample) |
| KR (8) | KR100889246B1 (enExample) |
| CN (6) | CN100436452C (enExample) |
| AP (2) | AP1588A (enExample) |
| AR (4) | AR040925A1 (enExample) |
| AT (9) | ATE326462T1 (enExample) |
| AU (7) | AU2002255452B2 (enExample) |
| BR (2) | BR0116493A (enExample) |
| CA (8) | CA2432799C (enExample) |
| CY (1) | CY1106297T1 (enExample) |
| DE (8) | DE60120219T2 (enExample) |
| DK (3) | DK1345922T3 (enExample) |
| ES (7) | ES2265450T3 (enExample) |
| HU (5) | HUP0400641A3 (enExample) |
| IL (8) | IL156369A0 (enExample) |
| MX (8) | MXPA03005605A (enExample) |
| MY (1) | MY140377A (enExample) |
| NO (5) | NO20032671L (enExample) |
| NZ (8) | NZ526469A (enExample) |
| PL (2) | PL210066B1 (enExample) |
| PT (3) | PT1345922E (enExample) |
| RU (1) | RU2355688C2 (enExample) |
| SI (2) | SI1353916T1 (enExample) |
| TW (2) | TWI290551B (enExample) |
| WO (8) | WO2002062789A1 (enExample) |
Families Citing this family (379)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982260B1 (en) | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1343781B1 (en) * | 2000-12-05 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| CA2432799C (en) * | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP4329003B2 (ja) * | 2001-03-23 | 2009-09-09 | バイエル コーポレイション | Ｒｈｏキナーゼ阻害剤 |
| AU2002252614B2 (en) | 2001-04-10 | 2006-09-14 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| EP1432416B1 (en) * | 2001-09-26 | 2011-01-19 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2002361846A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| CN100409840C (zh) * | 2002-01-10 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | GSK-3β抑制剂在制备增加骨生成的药物中的应用 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA04007697A (es) * | 2002-02-06 | 2004-11-10 | Vertex Pharma | Compuestos de heteroarilo utiles como inhibidores de gsk-3. |
| EP1485100B1 (en) * | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| AU2003225800A1 (en) * | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| ATE468336T1 (de) | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004009602A1 (en) * | 2002-07-23 | 2004-01-29 | Smithkline Beecham Corporation | Pyrazolopyrimidines as kinase inhibitors |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| PT1532145E (pt) * | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
| SI1532145T1 (sl) * | 2002-08-02 | 2007-02-28 | Vertex Pharma | Pirazolni sestavki, koristni kot inhibitorji GSK-3 |
| EP1537087B1 (fr) * | 2002-09-05 | 2012-11-28 | Aventis Pharma S.A. | Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant |
| FR2844267B1 (fr) * | 2002-09-05 | 2008-02-15 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
| AU2003255482A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| EP1558585B1 (en) * | 2002-10-04 | 2013-09-25 | Prana Biotechnology Limited | Neurologically-active compounds |
| KR100490893B1 (ko) * | 2002-10-11 | 2005-05-23 | (주) 비엔씨바이오팜 | 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물 |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| US7462613B2 (en) | 2002-11-19 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
| FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| US7309701B2 (en) | 2002-11-19 | 2007-12-18 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
| EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| US7601718B2 (en) * | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| WO2004087679A1 (en) * | 2003-04-01 | 2004-10-14 | Aponetics Ag | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
| WO2004105764A1 (en) * | 2003-06-02 | 2004-12-09 | Astrazeneca Ab | (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| WO2004112719A2 (en) * | 2003-06-19 | 2004-12-29 | Smithkline Beecham Corporation | Chemical compounds |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| JP2007500179A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン |
| US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
| US7417726B2 (en) * | 2003-09-19 | 2008-08-26 | Applied Biosystems Inc. | Normalization of data using controls |
| US20050221357A1 (en) * | 2003-09-19 | 2005-10-06 | Mark Shannon | Normalization of gene expression data |
| US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
| WO2005030131A2 (en) * | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
| DE602004022187D1 (de) | 2003-10-17 | 2009-09-03 | Astrazeneca Ab | 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs |
| CA2548172A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| AU2004297241A1 (en) * | 2003-12-09 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
| JP2007514759A (ja) | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| EP1745034A1 (en) | 2004-02-11 | 2007-01-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1723427A2 (en) * | 2004-02-26 | 2006-11-22 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b) |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| EP1732541A4 (en) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| JP2007533717A (ja) * | 2004-04-21 | 2007-11-22 | アストラゼネカ アクチボラグ | 化合物 |
| US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
| ES2505090T3 (es) * | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| ATE435858T1 (de) * | 2004-05-14 | 2009-07-15 | Vertex Pharma | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
| HRP20080120T5 (hr) * | 2004-05-14 | 2012-07-31 | Millennium@Pharmaceuticals | Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze |
| AU2012200416B2 (en) * | 2004-05-14 | 2014-07-31 | Millennium Pharmaceuticals, Inc. | "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase" |
| PL1905773T3 (pl) * | 2004-05-14 | 2012-12-31 | Millennium Pharm Inc | Związki i sposoby hamowania progresji mitotycznej poprzez hamowanie kinazy aurora |
| US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
| EP1750698A4 (en) * | 2004-05-20 | 2010-06-02 | Bayer Pharmaceuticals Corp | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES |
| JP2008500588A (ja) * | 2004-05-27 | 2008-01-10 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | フォトポリマー保護層用現像剤 |
| TW200612948A (en) * | 2004-07-01 | 2006-05-01 | Synta Pharmaceuticals Corp | 2-substituted heteroaryl compounds |
| US20060025406A1 (en) * | 2004-07-06 | 2006-02-02 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c- Met activity |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
| AR050948A1 (es) * | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
| JP5008567B2 (ja) * | 2004-09-30 | 2012-08-22 | テイボテク・フアーマシユーチカルズ | Ｈｉｖ阻害性５−ヘテロシクリルピリミジン |
| ES2380631T3 (es) * | 2004-09-30 | 2012-05-17 | Tibotec Pharmaceuticals | Pirimidinas sustituidas en posición 5 inhibidoras de VIH |
| CA2573976C (en) * | 2004-09-30 | 2014-04-29 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| EP1813609B1 (en) * | 2004-10-29 | 2013-06-19 | Msd K.K. | Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
| CA2587427A1 (en) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| JP5507049B2 (ja) * | 2004-12-30 | 2014-05-28 | アステックス、セラピューティックス、リミテッド | 医薬品 |
| WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| ES2336243T3 (es) * | 2005-01-26 | 2010-04-09 | Schering Corporation | Derivados de 3-(indazol-5-il)-(1,2,4)triazina y composiciones similares como inhibidores de proteina quinasa para el tratamiento del cancer. |
| CA2595834C (en) | 2005-02-04 | 2013-04-30 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| WO2006087530A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
| ES2347172T3 (es) * | 2005-02-16 | 2010-10-26 | Astrazeneca Ab | Compuestos quimicos. |
| RU2383545C2 (ru) * | 2005-03-15 | 2010-03-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| EP1863797A1 (en) * | 2005-03-23 | 2007-12-12 | AstraZeneca AB | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
| US7297700B2 (en) * | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| SI1869032T1 (sl) * | 2005-04-05 | 2008-12-31 | Astrazeneca Ab | Pirimidinski derivati za uporabo kot sredstva proti raku |
| GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
| WO2006108489A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
| US20090005396A1 (en) * | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| ES2545382T3 (es) | 2005-04-28 | 2015-09-10 | Mitsubishi Tanabe Pharma Corporation | Derivado de cianopiridina y su uso como medicamento |
| EP1885369B1 (en) | 2005-05-04 | 2015-09-23 | Evotec AG | Fused heterocyclic compounds, and compositions and uses thereof |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| JP2008540391A (ja) * | 2005-05-05 | 2008-11-20 | アストラゼネカ アクチボラグ | ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用 |
| EP1899323A2 (en) * | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| WO2006138304A2 (en) | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| JP2009504771A (ja) * | 2005-08-18 | 2009-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラジンキナーゼ阻害剤 |
| WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2622352C (en) * | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| UA96427C2 (en) * | 2005-09-30 | 2011-11-10 | Мийкана Терапьютикс, Инк. | Substituted pyrazole compounds |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2388259A1 (en) * | 2005-10-28 | 2011-11-23 | AstraZeneca AB | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| NZ567858A (en) * | 2005-11-01 | 2011-08-26 | Array Biopharma Inc | Pyridine compounds useful as Glucokinase activators |
| WO2007056163A2 (en) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CN101360740A (zh) * | 2005-11-16 | 2009-02-04 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶 |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US20070213319A1 (en) * | 2006-01-11 | 2007-09-13 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR20080103996A (ko) * | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| AU2007233737B2 (en) * | 2006-03-30 | 2012-11-29 | Janssen Sciences Ireland Uc | HIV inhibiting 5-amido substituted pyrimidines |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| ES2400375T3 (es) | 2006-04-07 | 2013-04-09 | Novartis Ag | Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE |
| ES2437997T3 (es) | 2006-04-14 | 2014-01-15 | Prana Biotechnology Limited | Método de tratamiento de la degeneración macular relacionada con la edad (AMD) |
| WO2007126126A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| CL2007001873A1 (es) | 2006-06-27 | 2008-01-04 | Takeda Pharmaceutical | Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20090209537A1 (en) * | 2006-06-30 | 2009-08-20 | Kyowa Hakko Kirin Co., Ltd. | Aurora inhibitors |
| UY30444A1 (es) * | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| EP2054413A2 (en) * | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| US7832809B2 (en) * | 2006-08-11 | 2010-11-16 | Schlumberger Technology Corporation | Degradation assembly shield |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008053812A1 (en) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and medicinal use thereof |
| DE602007004750D1 (de) * | 2006-11-02 | 2010-03-25 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| WO2008077086A1 (en) * | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| MX2009007005A (es) * | 2006-12-29 | 2009-07-09 | Tibotec Pharm Ltd | Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana. |
| JP5283633B2 (ja) * | 2006-12-29 | 2013-09-04 | テイボテク・フアーマシユーチカルズ | Ｈｉｖ阻害性５，６−置換ピリミジン |
| US8173647B2 (en) | 2007-02-06 | 2012-05-08 | Gordana Atallah | PI 3-kinase inhibitors and methods of their use |
| JPWO2008111441A1 (ja) | 2007-03-05 | 2010-06-24 | 協和発酵キリン株式会社 | 医薬組成物 |
| NZ579485A (en) * | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| EP2134709A1 (en) | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Aminopyridines useful as inhibitors of protein kinases |
| MX2009009590A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
| JP2010522194A (ja) * | 2007-03-20 | 2010-07-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害薬として有用なアミノピリミジン |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| NZ580343A (en) | 2007-04-13 | 2012-03-30 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| US20100204246A1 (en) * | 2007-04-18 | 2010-08-12 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer |
| CA2688584A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CA2694381A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5389785B2 (ja) * | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| US20100137398A1 (en) * | 2007-05-04 | 2010-06-03 | Novartis Ag | Use of hdac inhibitors for the treatment of gastrointestinal cancers |
| AU2008257044A1 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
| AU2008262291A1 (en) * | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| WO2009007753A2 (en) * | 2007-07-11 | 2009-01-15 | Astrazeneca Ab | 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer |
| KR20100038108A (ko) * | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| WO2009013545A2 (en) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
| TW200906818A (en) * | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
| AU2008282156B2 (en) * | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009027736A2 (en) * | 2007-08-27 | 2009-03-05 | Astrazeneca Ab | 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer |
| SI2209778T1 (sl) | 2007-09-21 | 2012-12-31 | Array Biopharma, Inc. | Piridin-2-il-amino-I, 2,4-tiadiazol derivati kot aktivatorji glukokinaze za zdravljenje sladkorne bolezni |
| MX2010003942A (es) | 2007-10-11 | 2010-04-30 | Glaxosmithkline Llc | Nuevos inhibidores de epoxido hidrolasa soluble y su uso. |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| MY152271A (en) * | 2008-02-21 | 2014-09-15 | Merck Sharp & Dohme | Novel compounds that are erk inhibitors |
| EP2254888B1 (en) | 2008-02-22 | 2014-12-24 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| PT2268635E (pt) | 2008-04-21 | 2015-10-06 | Taigen Biotechnology Co Ltd | Compostos heterocíclicos |
| US8844033B2 (en) | 2008-05-27 | 2014-09-23 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and media for detecting network anomalies using a trained probabilistic model |
| KR20110017445A (ko) * | 2008-06-11 | 2011-02-21 | 아스트라제네카 아베 | 암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체 |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| CA2729045A1 (en) * | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| CN102215816A (zh) * | 2008-09-03 | 2011-10-12 | 沃泰克斯药物股份有限公司 | 共晶和包含所述共晶的药物制剂 |
| NZ603495A (en) * | 2008-09-05 | 2014-05-30 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
| CN104230901A (zh) * | 2008-09-15 | 2014-12-24 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
| WO2010038060A1 (en) * | 2008-09-30 | 2010-04-08 | Astrazeneca Ab | Heterocyclic jak kinase inhibitors |
| US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| US8809343B2 (en) | 2008-12-26 | 2014-08-19 | Fudan University | Pyrimidine derivative, preparation method and use thereof |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| MY159327A (en) * | 2009-02-27 | 2016-12-25 | Ambit Biosciences Corp | Jak kinase modulating quinazoline derivatives and methods of use thereof |
| CA2660962A1 (en) | 2009-03-31 | 2010-09-30 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
| US8399663B2 (en) | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JP2012529513A (ja) * | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| CA2765044A1 (en) * | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| BRPI1011527A2 (pt) * | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
| CN102573480B (zh) * | 2009-06-09 | 2015-06-10 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| BRPI1011320A2 (pt) * | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de estiril-triazina e suas aplicações terapêuticas |
| EP2443106A1 (en) * | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| AU2010295690B2 (en) | 2009-09-16 | 2016-07-28 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| CN102596058B (zh) * | 2009-11-13 | 2015-10-21 | 直观外科手术操作公司 | 具有复设的闭合机构的末端执行器 |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| KR20130067487A (ko) | 2009-12-30 | 2013-06-25 | 아빌라 테라퓨틱스, 인크. | 단백질의 리간드-지정 공유 변형 |
| SA111320200B1 (ar) * | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| RU2012140021A (ru) | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2571359A4 (en) * | 2010-05-20 | 2013-10-23 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| LT2598482T (lt) | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| US20130296363A1 (en) * | 2010-09-01 | 2013-11-07 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
| WO2012030918A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
| US20130225614A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
| US20130225615A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US8633207B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
| AU2011296078B2 (en) | 2010-09-01 | 2015-06-18 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| AU2011296046B2 (en) * | 2010-09-01 | 2015-05-14 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolylaminoquinazoline |
| WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
| PH12013500880A1 (en) | 2010-11-10 | 2013-07-01 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| RU2014109897A (ru) | 2011-08-25 | 2015-09-27 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы серин/треонин киназы рак1 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2012311184A1 (en) * | 2011-09-22 | 2014-03-06 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| ES2655177T3 (es) * | 2012-02-17 | 2018-02-19 | Abbvie Inc. | Diaminopirimidinas útiles como inhibidores del virus respiratorio sincitial (VRS) humano |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US8916555B2 (en) | 2012-03-16 | 2014-12-23 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| SMT201800608T1 (it) | 2012-04-24 | 2019-01-11 | Vertex Pharma | Inibitori di dna-pk |
| US9296725B2 (en) * | 2012-05-24 | 2016-03-29 | Cellzome Limited | Heterocyclyl pyrimidine analogues as TYK2 inhibitors |
| SG11201408679XA (en) | 2012-06-26 | 2015-01-29 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CA2878621C (en) * | 2012-07-10 | 2020-09-15 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
| US9555115B2 (en) * | 2012-09-19 | 2017-01-31 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration with improved dissolution and/or absorption |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CN103191120B (zh) * | 2012-12-31 | 2015-11-25 | 刘强 | 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途 |
| CN103059002B (zh) * | 2012-12-31 | 2015-04-22 | 中山大学 | 具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用 |
| CN103202843B (zh) * | 2012-12-31 | 2015-04-29 | 刘强 | 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途 |
| CN103910716A (zh) * | 2013-01-07 | 2014-07-09 | 华东理工大学 | 2,4-二取代-环烷基[d]嘧啶类化合物及其用途 |
| AU2014244555B2 (en) | 2013-03-12 | 2018-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| GEP201706699B (en) | 2013-03-14 | 2017-07-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2014145485A2 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Map kinase modulators and uses thereof |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| WO2015003355A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| WO2015028848A1 (en) * | 2013-09-02 | 2015-03-05 | Piramal Enterprises Limited | Bicyclic heterocyclic compounds as multi-kinase inhibitors |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| HUE041877T2 (hu) | 2013-10-17 | 2019-06-28 | Vertex Pharma | (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3057955B1 (en) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| LT3089971T (lt) | 2014-01-01 | 2020-10-12 | Medivation Technologies Llc | Junginiai ir panaudojimo būdai |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| MX2016011837A (es) | 2014-03-13 | 2017-04-27 | Neuroderm Ltd | Composiciones de inhibidores de la dopa decarboxilasa. |
| EP3312164B1 (en) | 2014-03-28 | 2020-12-09 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
| PT3125883T (pt) | 2014-04-04 | 2020-10-12 | Iomet Pharma Ltd | Derivados de indol para utilização na medicina |
| CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| CN105367555B (zh) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| SI3604294T1 (sl) | 2014-10-13 | 2021-08-31 | Yuhan Corporation | Spojine in sestavki za moduliranje aktivnosti kinaze mutanta EGFR |
| JP6450010B2 (ja) | 2014-12-23 | 2019-01-09 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10227343B2 (en) * | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10752612B2 (en) | 2015-04-17 | 2020-08-25 | Ludwig Institute For Cancer Research Ltd | PLK4 inhibitors |
| KR20180011272A (ko) | 2015-05-28 | 2018-01-31 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나제 저해제로서 나프티리딘 화합물 |
| JP2018135268A (ja) * | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩 |
| EP3324976A4 (en) | 2015-07-21 | 2019-03-27 | Millennium Pharmaceuticals, Inc. | ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| CN113750101A (zh) * | 2015-12-10 | 2021-12-07 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| CN105503754B (zh) * | 2015-12-11 | 2017-11-17 | 浙江大学 | 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用 |
| CN105384702B (zh) * | 2015-12-11 | 2018-04-10 | 浙江大学 | 三取代均三嗪类化合物及其制备方法 |
| CN105399695B (zh) * | 2015-12-11 | 2019-04-19 | 浙江大学 | 三嗪类化合物及其制备方法和用途 |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| WO2017165255A1 (en) | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| US10968227B2 (en) * | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
| FR3064275B1 (fr) | 2017-03-21 | 2019-06-07 | Arkema France | Procede de chauffage et/ou climatisation d'un vehicule |
| CN110691776A (zh) | 2017-05-30 | 2020-01-14 | 巴斯夫欧洲公司 | 吡啶和吡嗪化合物 |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| EP3645121B8 (en) | 2017-06-28 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CN110573501B (zh) * | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CA3063616A1 (en) | 2017-06-30 | 2019-12-06 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| US11440904B2 (en) * | 2017-08-28 | 2022-09-13 | Zhihong Chen | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof |
| WO2019046316A1 (en) * | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
| GEP20227344B (en) | 2017-10-27 | 2022-01-25 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| KR20200090198A (ko) * | 2017-11-23 | 2020-07-28 | 바이오메드 엑스 게엠베하 | 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체 |
| WO2019113311A1 (en) * | 2017-12-06 | 2019-06-13 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with plk4 inhibitors |
| WO2019178129A1 (en) | 2018-03-13 | 2019-09-19 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| JP7590185B2 (ja) * | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| CN115925705B (zh) * | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| TW202106682A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 作為jak激酶抑制劑之酯類及碳酸酯類嘧啶化合物 |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| EP4007757B1 (en) * | 2019-08-01 | 2025-09-10 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| PT4031547T (pt) | 2019-09-18 | 2024-08-27 | Takeda Pharmaceuticals Co | Inibidores de calicreína plasmática e utilizações dos mesmos |
| CN110483493A (zh) * | 2019-09-19 | 2019-11-22 | 广东工业大学 | 一种二唑类衍生物及其制备方法和应用 |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN117355523A (zh) * | 2021-03-17 | 2024-01-05 | 武田药品工业株式会社 | 血浆激肽释放酶的多环抑制剂 |
| IL307165A (en) * | 2021-03-26 | 2023-11-01 | Sumitomo Pharma Oncology Inc | ALK-5 inhibitors and their uses |
| IL308346A (en) | 2021-05-11 | 2024-01-01 | Oric Pharmaceuticals Inc | Polo like kinase 4 inhibitors |
| UY39832A (es) | 2021-06-28 | 2023-01-31 | Blueprint Medicines Corp | Inhibidores de cdk2 |
| KR102692529B1 (ko) * | 2021-07-01 | 2024-08-08 | 한국원자력의학원 | Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물 |
| CN116354938B (zh) * | 2021-12-28 | 2024-02-20 | 沈阳药科大学 | 一类喹唑啉衍生物与其类似物的制备方法及应用 |
| CN114276302B (zh) * | 2022-01-11 | 2023-07-25 | 山东百启生物医药有限公司 | 一种制备2,4-二氨基喹唑啉衍生物的方法 |
| CN116813595B (zh) * | 2022-03-28 | 2025-07-18 | 上海医药工业研究院有限公司 | 喹唑啉类衍生物、其制备方法、药物组合物及应用 |
| WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
| CN117736198A (zh) * | 2022-09-21 | 2024-03-22 | 科辉智药生物科技(深圳)有限公司 | 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用 |
| CN115403568B (zh) * | 2022-09-21 | 2023-09-29 | 中山大学 | 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用 |
| WO2024178335A2 (en) * | 2023-02-23 | 2024-08-29 | Accutar Biotechnology, Inc. | Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US18436A (en) * | 1857-10-20 | And saml | ||
| US3133081A (en) | 1964-05-12 | J-aminoindazole derivatives | ||
| US2585906A (en) | 1952-02-12 | Quaternary salts of pyrimdjines | ||
| US3935183A (en) | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102194L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| SE8102193L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| JPS58124773A (ja) | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| EP0136976A3 (de) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
| DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
| JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
| JPH0665237A (ja) | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
| JPH10509708A (ja) | 1994-11-10 | 1998-09-22 | コア セラピューティクス，インコーポレイティド | プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物 |
| IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| JPH10130150A (ja) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
| IL129091A0 (en) | 1996-10-11 | 2000-02-17 | Warner Lambert Co | Aspartate ester inhibitors of interleukin-1beta converting enzyme |
| DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| CN1138472C (zh) | 1997-10-10 | 2004-02-18 | 西托维亚公司 | 二肽型编程性细胞死亡抑制剂及其用途 |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
| KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
| CA2323439A1 (en) | 1998-03-16 | 1999-09-23 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| WO1999062518A1 (en) | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
| WO2000003901A1 (de) * | 1998-07-16 | 2000-01-27 | Continental Teves Ag & Co. Ohg | Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen |
| CA2339188A1 (en) | 1998-08-21 | 2000-03-02 | Dupont Pharmaceuticals Company | Isoxazolo¬4,5-d|pyrimidines as crf antagonists |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| ATE294796T1 (de) * | 1998-10-08 | 2005-05-15 | Astrazeneca Ab | Chinazolin derivate |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| IL144215A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| PT1165085E (pt) | 1999-03-30 | 2006-10-31 | Novartis Ag | Derivados de ftalazina para tratar doencas inflamatorias |
| WO2000078757A1 (en) | 1999-06-17 | 2000-12-28 | Shionogi Bioresearch Corp. | Inhibitors of il-12 production |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| AR032130A1 (es) | 1999-08-13 | 2003-10-29 | Vertex Pharma | Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto |
| AU770600B2 (en) | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| KR20020059826A (ko) | 1999-11-30 | 2002-07-13 | 데이비드 존 우드 | 면역 억제제로 유용한 2,4-디아미노피리미딘 화합물 |
| AU784878B2 (en) | 1999-12-02 | 2006-07-13 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof |
| MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6376489B1 (en) | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| IL145757A (en) | 2000-02-05 | 2007-12-03 | Vertex Pharma | History of pyrazole and pharmaceutical preparations containing them |
| WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| JP4806154B2 (ja) | 2000-04-03 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター |
| WO2001079198A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
| JP3890184B2 (ja) * | 2000-05-15 | 2007-03-07 | Ｎｅｃパーソナルプロダクツ株式会社 | 電源装置及びその電力制御方法、情報処理機器 |
| MXPA02011974A (es) | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Derivados de quinazolina sustituidos y su uso como inhibidores. |
| MY139078A (en) | 2000-07-21 | 2009-08-28 | Schering Corp | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| CN1518543A (zh) | 2000-08-31 | 2004-08-04 | �Ʒ� | 吡唑衍生物和它们作为蛋白激酶抑制剂的用途 |
| NZ525016A (en) | 2000-09-15 | 2004-10-29 | Vertex Pharma | Isoxazoles and their use as inhibitors of ERK |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
| US6641579B1 (en) * | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| WO2002047690A1 (en) | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| DE10061863A1 (de) | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| CA2432799C (en) | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2441733A1 (en) | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1389206B1 (en) | 2001-04-13 | 2006-09-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1383771A1 (en) | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| US6884804B2 (en) | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| US6689778B2 (en) | 2001-07-03 | 2004-02-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and Lck protein kinases |
| WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| US6569499B2 (en) * | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
| EP1474147B1 (en) | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| EP1485100B1 (en) | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| ATE468336T1 (de) | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| AU2003225800A1 (en) | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| ES2289279T3 (es) | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
| US20030207873A1 (en) | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| JP4570955B2 (ja) | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| PT1532145E (pt) | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
| CA2622352C (en) | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| WO2008077086A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
-
2001
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en not_active Ceased
- 2001-12-19 IL IL15636901A patent/IL156369A0/xx active IP Right Grant
- 2001-12-19 AT AT01994510T patent/ATE326462T1/de active
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en not_active Ceased
- 2001-12-19 AT AT01271061T patent/ATE327989T1/de active
- 2001-12-19 EP EP01993360A patent/EP1345926B1/en not_active Expired - Lifetime
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 AT AT01273861T patent/ATE354573T1/de active
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 DE DE60120219T patent/DE60120219T2/de not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en not_active Ceased
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/ja active Pending
- 2001-12-19 CN CNB018221025A patent/CN100436452C/zh not_active Expired - Fee Related
- 2001-12-19 AT AT01993360T patent/ATE326461T1/de active
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 DK DK01271061T patent/DK1345922T3/da active
- 2001-12-19 EP EP01985059A patent/EP1345925B1/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en not_active Ceased
- 2001-12-19 EP EP01271061A patent/EP1345922B1/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/pt not_active IP Right Cessation
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/ko not_active Expired - Fee Related
- 2001-12-19 PT PT01271061T patent/PT1345922E/pt unknown
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/es active IP Right Grant
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/es active IP Right Grant
- 2001-12-19 DE DE60126828T patent/DE60126828T2/de not_active Expired - Lifetime
- 2001-12-19 PT PT01994323T patent/PT1353916E/pt unknown
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/ko not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/ko not_active Expired - Fee Related
- 2001-12-19 DK DK01994323T patent/DK1353916T3/da active
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/ja not_active Expired - Fee Related
- 2001-12-19 EP EP01273861A patent/EP1355905B1/en not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/ko not_active Expired - Fee Related
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en not_active Ceased
- 2001-12-19 IL IL15638901A patent/IL156389A0/xx active IP Right Grant
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en not_active Ceased
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/ko not_active Abandoned
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 ES ES01993360T patent/ES2265450T3/es not_active Expired - Lifetime
- 2001-12-19 EP EP10184271A patent/EP2264028A1/en not_active Withdrawn
- 2001-12-19 ES ES01273861T patent/ES2280313T3/es not_active Expired - Lifetime
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/ru not_active IP Right Cessation
- 2001-12-19 NZ NZ526470A patent/NZ526470A/xx not_active IP Right Cessation
- 2001-12-19 IL IL15640701A patent/IL156407A0/xx not_active IP Right Cessation
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/ja not_active Expired - Fee Related
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-19 AT AT01985059T patent/ATE326460T1/de active
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/ko not_active Expired - Fee Related
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/ja not_active Expired - Fee Related
- 2001-12-19 SI SI200130656T patent/SI1353916T1/sl unknown
- 2001-12-19 SI SI200130722T patent/SI1355905T1/sl unknown
- 2001-12-19 IL IL15640801A patent/IL156408A0/xx unknown
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 PT PT01273861T patent/PT1355905E/pt unknown
- 2001-12-19 CN CNA018221033A patent/CN1486310A/zh active Pending
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/zh not_active Expired - Fee Related
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/hu unknown
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/hu unknown
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/ja not_active Expired - Fee Related
- 2001-12-19 DE DE60123283T patent/DE60123283T2/de not_active Expired - Lifetime
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 ES ES06011799T patent/ES2375491T3/es not_active Expired - Lifetime
- 2001-12-19 EP EP01994510A patent/EP1345927B1/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/pt not_active IP Right Cessation
- 2001-12-19 DE DE60119775T patent/DE60119775T2/de not_active Expired - Lifetime
- 2001-12-19 ES ES01271061T patent/ES2266095T3/es not_active Expired - Lifetime
- 2001-12-19 CN CNB018221351A patent/CN100408573C/zh not_active Expired - Fee Related
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 AT AT06011799T patent/ATE528303T1/de not_active IP Right Cessation
- 2001-12-19 ES ES01994323T patent/ES2272567T3/es not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/es active IP Right Grant
- 2001-12-19 AT AT01994323T patent/ATE340172T1/de active
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/es active IP Right Grant
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/hu unknown
- 2001-12-19 PL PL363246A patent/PL210066B1/pl unknown
- 2001-12-19 DE DE60119774T patent/DE60119774T2/de not_active Expired - Lifetime
- 2001-12-19 PL PL363244A patent/PL210414B1/pl not_active IP Right Cessation
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/zh not_active Expired - Fee Related
- 2001-12-19 DK DK01273861T patent/DK1355905T3/da active
- 2001-12-19 EP EP01994323A patent/EP1353916B1/en not_active Expired - Lifetime
- 2001-12-19 IL IL15636801A patent/IL156368A0/xx not_active IP Right Cessation
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/es active IP Right Grant
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 DE DE60119776T patent/DE60119776T2/de not_active Expired - Lifetime
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/es not_active Application Discontinuation
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 EP EP06011799A patent/EP1702920B1/en not_active Expired - Lifetime
- 2001-12-19 ES ES01985059T patent/ES2265446T3/es not_active Expired - Lifetime
- 2001-12-19 ES ES01994510T patent/ES2265452T3/es not_active Expired - Lifetime
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/hu unknown
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/hu unknown
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/ja not_active Expired - Fee Related
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/zh active Pending
- 2001-12-20 AR ARP010105963A patent/AR040925A1/es active IP Right Grant
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/ko not_active Abandoned
- 2001-12-20 AR ARP010105961A patent/AR042398A1/es unknown
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/es not_active Application Discontinuation
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 EP EP01991439A patent/EP1345928B1/en not_active Expired - Lifetime
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/ja active Pending
- 2001-12-20 AT AT01991439T patent/ATE353890T1/de not_active IP Right Cessation
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en not_active Ceased
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/ja active Pending
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/es unknown
- 2001-12-20 DE DE60126658T patent/DE60126658T2/de not_active Expired - Lifetime
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en not_active Ceased
- 2001-12-20 DE DE60119777T patent/DE60119777T2/de not_active Expired - Lifetime
- 2001-12-20 EP EP01994347A patent/EP1345929B1/en not_active Expired - Lifetime
- 2001-12-20 AT AT01994347T patent/ATE326463T1/de not_active IP Right Cessation
- 2001-12-20 AR ARP010105960A patent/AR042397A1/es active IP Right Grant
- 2001-12-20 AR ARP010105962A patent/AR042169A1/es active IP Right Grant
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/ko not_active Withdrawn
- 2001-12-20 AU AU3116602A patent/AU3116602A/xx active Pending
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW090131846A patent/TWI290551B/zh not_active IP Right Cessation
- 2001-12-25 TW TW095139649A patent/TWI313269B/zh not_active IP Right Cessation
-
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/no not_active Application Discontinuation
- 2003-06-12 NO NO20032670A patent/NO328537B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032703A patent/NO328501B1/no not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/no unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
-
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/ja not_active Withdrawn
-
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/el unknown
-
2008
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/ja not_active Withdrawn
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/ja not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/ja active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/ja active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/ja active Pending
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/ja active Pending
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/ja active Pending
-
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/ja not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/ja not_active Withdrawn
-
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
-
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
-
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/ja active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517894A5 (enExample) | ||
| RU2003122209A (ru) | Производные пиразола, полезные в качестве ингибиторов протеинкиназы | |
| EP1400518B1 (en) | Heterocyclic compound derivatives and medicines | |
| JP4570955B2 (ja) | プロテインキナーゼ阻害活性を持つイミダゾール類 | |
| US6743791B2 (en) | Heterocyclic inhibitors of ERK2 and uses thereof | |
| JP5030229B2 (ja) | プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−ａ］ピリミジン | |
| JP2004509113A5 (enExample) | ||
| CZ268493A3 (en) | Sulfonamide compounds, process of their preparation and pharmaceutical preparations in which they are comprised | |
| ES2212657T3 (es) | Pirazinas sustituidas piridin-4-il o pirimidin-4-il. | |
| WO1999061444A3 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
| BRPI0616630A2 (pt) | compostos de pirazol substituìdos | |
| US20030100558A1 (en) | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | |
| JPWO2002088084A6 (ja) | 複素環誘導体及び医薬 | |
| JP2004518743A5 (enExample) | ||
| JP2004509116A5 (enExample) | ||
| JP2004509114A5 (enExample) | ||
| JP2005509592A (ja) | プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール | |
| JP2004505964A5 (enExample) | ||
| JP2008519059A5 (enExample) | ||
| JPS63146882A (ja) | イミダゾ［４，５―ｂ］ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 | |
| KR100848205B1 (ko) | 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물 | |
| CN115785074B (zh) | Parp7抑制剂及其用途 | |
| EP0644191A1 (en) | Pyridine compound and medicinal use thereof | |
| CA2345944A1 (en) | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands | |
| US4866066A (en) | Thiomethylpyridine derivatives and their use for eliciting a bronchosecretolytic or mucolytic response |